

MEDICINES FOR SMOKING CESSATION: GLOBAL MARKETS



PHM154A
September 2013

Anand Gijare
Project Analyst

ISBN: 1-56965-544-8

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481
866-285-7215, 781-489-7301
www.bccresearch.com
Custom Reports:
carol.laverty@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
SCOPE OF REPORT	2
INTENDED AUDIENCE	2
INFORMATION SOURCES	3
ANALYST CREDENTIALS	3
RELATED REPORTS	3
BCC ONLINE SERVICES	4
DISCLAIMER	4
CHAPTER 2 SUMMARY	6
<i>SUMMARY TABLE SIZE OF GLOBAL SMOKING CESSATION MEDICINE MARKET BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	8
<i>SUMMARY FIGURE SIZE OF GLOBAL SMOKING CESSATION MEDICINE MARKET BY REGION, 2011-2018 (\$ MILLIONS)</i>	8
CHAPTER 3 OVERVIEW	12
SMOKING AND HEALTH HAZARDS	12
CURRENT TRENDS IN THE TOBACCO INDUSTRY	13
HEALTH HAZARDS OF SMOKING	14
METHODS OF SMOKING CESSATION	16
SMOKING CESSATION WITHOUT ASSISTANCE	16
SMOKING CESSATION WITH EXPERT INTERVENTIONS	18
SMOKING CESSATION WITH MEDICATION	18
HEALTH BENEFITS OF SMOKING CESSATION	18
<i>TABLE 1 BENEFITS OF SMOKING CESSATION</i>	19
TRENDS IN SMOKING CESSATION	20
ROLE OF NICOTINE	21
<i>FIGURE 1 NICOTINE MOLECULE: 3-[(2S)-1-METHYLPYRROLIDINE-2-YL]PYRIDINE</i>	21
UNDERSTANDING NICOTINE ADDICTION	22
<i>TABLE 2 GENERAL CRITERIA FOR DRUG DEPENDENCE</i>	23
UNDERSTANDING NICOTINE ABSORPTION MECHANISM	24
UNDERSTANDING WITHDRAWAL SYMPTOMS OF NICOTINE	25
CHAPTER 4 SMOKING CESSATION MEDICINES	28
<i>TABLE 3 CLASSIFICATION OF SMOKING CESSATION MEDICINES BASED ON MODE OF ACTION</i>	29
NICOTINE REPLACEMENT THERAPY	29
<i>TABLE 4 CLASSIFICATION OF NICOTINE REPLACEMENT THERAPY BASED ON DRUG DELIVERY SYSTEM</i>	29
NICOTINE REPLACEMENT THERAPY: ORAL MUCOSA DELIVERY SYSTEM	30
Nicotine Gum	30
<i>TABLE 5 NICOTINE GUM DOSAGES AND SCHEDULES</i>	30
Key Brands	31
<i>TABLE 6 KEY BRANDS AND MARKETERS OF NICOTINE GUMS</i>	32

TOPIC	PAGE NO.
Nicotine Lozenges	32
<i>TABLE 7 NICOTINE LOZENGE DOSAGE AND SCHEDULE</i>	32
<i>TABLE 8 KEY BRANDS AND MARKETERS OF NICOTINE LOZENGES</i>	33
Nicotine Tablets	33
<i>TABLE 9 KEY BRANDS AND MARKETERS OF NICOTINE TABLETS</i>	34
Nicotine Inhalers	34
<i>TABLE 10 KEY BRANDS AND MARKETERS OF NICOTINE INHALERS</i>	34
Nicotine Mouth Sprays	35
<i>TABLE 11 KEY BRANDS AND MARKETERS OF NICOTINE MOUTH SPRAYS</i>	35
NICOTINE REPLACEMENT THERAPY: TRANSDERMAL DELIVERY SYSTEM	35
Nicotine Patches	35
<i>TABLE 12 NICOTINE PATCH DOSAGE AND SCHEDULE</i>	36
<i>TABLE 13 KEY BRANDS AND MARKETERS OF NICOTINE PATCHES</i>	37
NICOTINE REPLACEMENT THERAPY: NASAL DELIVERY SYSTEM	37
Nicotine Nasal Sprays	37
<i>TABLE 14 KEY BRANDS AND MARKETERS OF NICOTINE NASAL SPRAYS</i>	37
NON-NICOTINE THERAPIES	38
CHANTIX/CHAMPIX (VARENICLINE TARTRATE)	38
Mechanism of Action	38
Marketing	38
<i>TABLE 15 CHANTIX/CHAMPIX SALES REVENUE, 2007-2012 (\$ MILLIONS)</i>	39
Zyban (bupropion HCl)	39
R&D IN SMOKING CESSATION MEDICINES	40
DEVELOPMENTS IN THE PIPELINE (NICOTINE REPLACEMENT THERAPY)	40
NICOTINE VACCINES	40
<i>TABLE 16 NICOTINE VACCINES IN DEVELOPMENT PHASE AS OF JANUARY 2013</i>	41
NICOTINE ORALLY DISSOLVABLE FILMS	41
VERY LOW NICOTINE CIGARETTES	42
CYTISINE (TABEX)	42
DEVELOPMENTS IN THE PIPELINE (NON-NICOTINE THERAPY)	43
<i>TABLE 17 DEVELOPMENTS IN THE PIPELINE (NON-NICOTINE)</i>	43
GSK598809 SELECTIVE D3 RECEPTOR ANTAGONIST	44
D-CYCLOSERINE	44
<i>TABLE 18 CLINICAL TRIALS OF D-CYCLOSERINE</i>	44
EVT 302	44
SELEGILINE	45
NALMEFENE	45
CHAPTER 5 THE GLOBAL SMOKING CESSATION MEDICINE MARKET	47
SMOKING CESSATION MARKET REVENUE, 2012	47
SMOKING CESSATION MEDICINE MARKET FORECAST, 2013-2018	47
<i>TABLE 19 SMOKING CESSATION MEDICINE GLOBAL MARKET FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	48
<i>FIGURE 2 SMOKING CESSATION MEDICINE GLOBAL MARKET FORECAST, 2011-2018 (\$ MILLIONS)</i>	48
GLOBAL MARKET FORECAST BY CLASSIFICATION OF SMOKING CESSATION MEDICINES, 2013-2018	49

TOPIC	PAGE NO.
<i>TABLE 20 SMOKING CESSATION MEDICINE GLOBAL MARKET FORECAST BY CLASSIFICATION, THROUGH 2018 (\$ MILLIONS)</i>	49
<i>FIGURE 3 SMOKING CESSATION MEDICINE GLOBAL MARKET FORECAST BY CLASSIFICATION, 2011-2018 (\$ MILLIONS)</i>	50
GLOBAL MARKET FORECAST BY TYPE OF SALES, 2013-2018	50
<i>TABLE 21 GLOBAL SMOKING CESSATION MEDICINES BY TYPE OF SALES</i>	50
<i>TABLE 22 SMOKING CESSATION MEDICINES FORECAST BY TYPE OF SALES, THROUGH 2018 (\$ MILLIONS)</i>	51
<i>FIGURE 4 SMOKING CESSATION MEDICINE GLOBAL MARKET FORECAST BY TYPE OF SALES, 2011-2018 (\$ MILLIONS)</i>	51
GLOBAL SMOKING CESSATION MEDICINE MARKET FORECAST BY CATEGORY, 2013-2018	52
<i>TABLE 23 SIZE OF GLOBAL SMOKING CESSATION MEDICINE MARKET BY CATEGORY, THROUGH 2018 (\$ MILLIONS)</i>	53
<i>FIGURE 5 SIZE OF GLOBAL SMOKING CESSATION MEDICINE MARKET BY CATEGORY, 2011-2018 (\$ MILLIONS)</i>	53
GLOBAL NICOTINE REPLACEMENT THERAPY MARKET FORECAST BY CATEGORY, 2013-2018	55
<i>TABLE 24 GLOBAL NICOTINE REPLACEMENT THERAPY MARKET FORECAST BY CATEGORY, THROUGH 2018 (\$ MILLIONS)</i>	56
<i>FIGURE 6 GLOBAL NICOTINE REPLACEMENT THERAPY MARKET FORECAST BY CATEGORY, 2011-2018 (\$ MILLIONS)</i>	56
CHAPTER 6 LEADING MARKETS FOR SMOKING CESSATION MEDICINES	59
GLOBAL MARKET FORECAST BY REGION FOR SMOKING CESSATION MEDICINES, 2013-2018	59
EMERGING MARKETS ARE NEW TARGET MARKETS FOR SMOKING CESSATION, THROUGH 2018	59
Quit Rates are High in Developed Countries	59
Decrease in Smoking Rates Have Reached Saturation Point in Developed Markets	60
Smoking Rates are Increasing in Developing Markets	60
STRATEGIC INITIATIVES TO INCREASE SMOKING CESSATION IN DEVELOPING COUNTRIES	60
Developing and Poor Countries Sign WHO FCTC Treaty	61
WHO FCTC Progress Report 2012	61
<i>TABLE 25 ARTICLES REPORTING HIGHEST IMPLEMENTATION RATES: 2012 WHO FCTC PROGRESS REPORT (%)</i>	62
<i>TABLE 26 ARTICLES REPORTING MODERATE IMPLEMENTATION RATES: 2012 WHO FCTC PROGRESS REPORT (%)</i>	62
<i>TABLE 27 ARTICLES REPORTING LOWEST IMPLEMENTATION RATES: 2012 WHO FCTC PROGRESS REPORT (%)</i>	63
<i>FIGURE 7 GLOBAL IMPLEMENTATION OF ARTICLES: 2012 FCTC REPORT (%)</i>	63
<i>TABLE 28 GLOBAL IMPLEMENTATION OF FCTC ARTICLES: 2012 REPORT</i>	64
Implementation of Article 14 in 2012	66
<i>TABLE 29 GLOBAL IMPLEMENTATION OF ARTICLE 14 OF FCTC, 2012</i>	67
<i>TABLE 30 SIZE OF GLOBAL SMOKING CESSATION MEDICINE MARKET BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	69
<i>FIGURE 8 SIZE OF GLOBAL SMOKING CESSATION MEDICINE MARKET BY REGION, 2011-2018 (\$ MILLIONS)</i>	69
THE U.S.: SMOKING CESSATION MARKET	70

TOPIC	PAGE NO.
CIGARETTE SMOKING DECLINES IN THE U.S.	71
THE U.S. SMOKING CESSATION MEDICINE MARKET	71
<i>TABLE 31 SMOKING CESSATION BRANDS IN THE U.S. MARKET, 2012</i>	72
NEW ENTRANTS EYE THE U.S. MARKET	72
THE U.S.: SMOKING CESSATION MARKET REVENUE, 2012	73
THE U.S.: MARKET FORECAST FOR SMOKING CESSATION MEDICINES, 2013-2018	73
<i>TABLE 32 SMOKING CESSATION MEDICINE MARKET IN THE U.S., THROUGH 2018 (\$ MILLIONS)</i>	73
<i>FIGURE 9 SMOKING CESSATION MEDICINE MARKET IN THE U.S., 2011-2018 (\$ MILLIONS)</i>	73
CANADA: SMOKING CESSATION MARKET	74
CANADA SMOKING CESSATION MEDICINE MARKET	75
<i>TABLE 33 SMOKING CESSATION BRANDS IN CANADA MARKET: 2012</i>	76
NEW ENTRANTS IN CANADIAN MARKET	76
CANADA: SMOKING CESSATION MARKET REVENUE 2012	76
CANADA: MARKET FORECAST FOR SMOKING CESSATION MEDICINES, 2013-2018	77
<i>TABLE 34 SMOKING CESSATION MEDICINE MARKET IN CANADA, THROUGH 2018 (\$ MILLIONS)</i>	77
EUROPE: SMOKING CESSATION MEDICINE MARKET	77
<i>TABLE 35 SMOKING CESSATION BRANDS IN EUROPEAN MARKET: 2012</i>	78
EUROPE: SMOKING CESSATION MARKET REVENUE, 2012	78
EUROPE: MARKET FORECAST FOR SMOKING CESSATION MEDICINES, 2013-2018	79
<i>TABLE 36 SMOKING CESSATION MEDICINE MARKET IN EUROPE, THROUGH 2018 (\$ MILLIONS)</i>	79
<i>FIGURE 10 SMOKING CESSATION MEDICINE MARKET IN EUROPE, 2011-2018 (\$ MILLIONS)</i>	79
THE U.K.: SMOKING CESSATION MEDICINE MARKET	80
TOBACCO INDUSTRY IN THE U.K.	80
SMOKING BANS AND REGULATING NICOTINE PRODUCTS	80
THE U.K.: SMOKING CESSATION MARKET REVENUE, 2012	81
<i>TABLE 37 SMOKING CESSATION BRANDS IN THE U.K. MARKET: 2012</i>	81
THE U.K.: MARKET FORECAST FOR SMOKING CESSATION MEDICINES, 2013-2018	82
<i>TABLE 38 SMOKING CESSATION MEDICINE MARKET IN THE U.K., THROUGH 2018 (\$ MILLIONS)</i>	82
<i>FIGURE 11 SMOKING CESSATION MEDICINE MARKET IN THE U.K., 2011-2018 (\$ MILLIONS)</i>	82
FRANCE: SMOKING CESSATION MEDICINE MARKET	83
FRANCE: MARKET FORECAST FOR SMOKING CESSATION MEDICINES, 2013-2018	84
<i>TABLE 39 SMOKING CESSATION MEDICINE MARKET IN FRANCE, THROUGH 2018 (\$ MILLIONS)</i>	84
<i>FIGURE 12 SMOKING CESSATION MEDICINE MARKET IN FRANCE, 2011-2018 (\$ MILLIONS)</i>	84
OTHER PROMISING EUROPEAN MARKETS	85
GERMANY HAS LOW POTENTIAL FOR SMOKING CESSATION MEDICATION	85
ASIA PACIFIC: SMOKING CESSATION MEDICINE MARKET	85
<i>TABLE 40 SMOKING CESSATION MEDICINE MARKET IN ASIA PACIFIC, THROUGH 2018 (\$ MILLIONS)</i>	86

TOPIC	PAGE NO.
AUSTRALIA: SMOKING CESSATION MEDICINE MARKET	87
<i>TABLE 41 SMOKING CESSATION BRANDS IN AUSTRALIA MARKET: 2012</i>	88
AUSTRALIA: MARKET FORECAST FOR SMOKING CESSATION MEDICINES, 2013-2018	88
<i>TABLE 42 SMOKING CESSATION MEDICINE MARKET IN AUSTRALIA, THROUGH 2018 (\$ MILLIONS)</i>	88
NEW ZEALAND: SMOKING CESSATION MEDICINE MARKET	89
<i>TABLE 43 SMOKING CESSATION BRANDS IN NEW ZEALAND MARKET: 2012</i>	90
JAPAN: SMOKING CESSATION MEDICINE MARKET	91
JAPAN: MARKET FORECAST FOR SMOKING CESSATION MEDICINES, 2013-2018	92
EMERGING MARKETS FOR SMOKING CESSATION MEDICINES	92
<i>TABLE 44 SMOKING CESSATION MEDICINE MARKET IN EMERGING MARKETS, THROUGH 2018 (\$ MILLIONS)</i>	93
EMERGING MARKETS: MARKET FORECAST FOR SMOKING CESSATION MEDICINES, 2013-2018	93
CHINA: SMOKING CESSATION MEDICINE MARKET	93
SMOKING PREVALENCE AND TOBACCO CONTROL INITIATIVES	93
SMOKING CESSATION MEDICINE MARKET IN CHINA	95
CHINA: MARKET FORECAST FOR SMOKING CESSATION MEDICINES, 2013-2018	95
CHINA: MARKET POTENTIAL COULD BE TAPPED THROUGH COPD TREATMENT	95
INDIA: SMOKING CESSATION MEDICINE MARKET	96
TOBACCO CONTROL INITIATIVES IN INDIA	96
SMOKING CESSATION MEDICINE MARKET IN INDIA	97
<i>TABLE 45 SMOKING CESSATION BRANDS IN INDIAN MARKET: 2012</i>	98
GENERIC BUPROPION HCL LEADS INDIAN MARKET FOR SMOKING CESSATION	98
INDIA: MARKET FORECAST FOR SMOKING CESSATION MEDICINES, 2013-2018	99
<i>TABLE 46 SMOKING CESSATION MEDICINE MARKET IN INDIA, THROUGH 2018 (\$ MILLIONS)</i>	99
BRAZIL: SMOKING CESSATION MEDICINE MARKET	99
SMOKING CESSATION MEDICINE MARKET IN BRAZIL	100
<i>TABLE 47 SMOKING CESSATION BRANDS IN BRAZILIAN MARKET, 2012</i>	100
BRAZIL: MARKET FORECAST FOR SMOKING CESSATION MEDICINES, 2013-2018	101
<i>TABLE 48 SMOKING CESSATION MEDICINE MARKET IN BRAZIL, THROUGH 2018 (\$ MILLIONS)</i>	101
CHAPTER 7 SMOKING CESSATION INDUSTRY AND MARKET ANALYSES	103
GLOBAL MARKET FOR SMOKING CESSATION MEDICINES	104
PESTLE ANALYSIS	104
Political and Legal Interventions Influence Markets	104
<i>TABLE 49 INITIATIVES IMPLEMENTED BY PARTIES TO FCTC TREATY (%)</i>	106
Socioeconomic Factors	106
<i>TABLE 50 PROJECTED GLOBAL CAUSE OF DEATH (%)</i>	108
<i>TABLE 51 PUBLIC HEALTH BURDEN DUE TO SMOKING-RELATED DISEASES (\$ BILLIONS)</i>	108
Technology Developments	108
<i>FIGURE 13 GLOBAL STUDIES ON TOBACCO DEPENDENCE AND SMOKING CESSATION, BY REGION (NO. OF ONGOING STUDIES)</i>	109

TOPIC	PAGE NO.
<i>TABLE 52 SWOT ANALYSIS OF SMOKING CESSATION MEDICINES</i>	110
COMPETITIVE ANALYSIS AND BENCHMARKING	111
TOBACCO TRANSFORMATION STRATEGY	111
DIFFERENTIATION BETWEEN SMOKING CESSATION MEDICINES AND ALTERNATIVES TO CIGARETTES	112
<i>TABLE 53 COMPARING SMOKING CESSATION MEDICINES AND OTHER NICOTINE DELIVERY SYSTEMS</i>	112
COLLABORATIONS AND COMBINATIONS	112
INDUSTRY OPINION ON FUTURE OF THE SMOKING CESSATION MEDICINE INDUSTRY	113
UNTAPPED POTENTIAL OF SMOKING CESSATION MARKET COULD BE \$60 BILLION	114
CHAPTER 8 COMPANY PROFILES	116
22ND CENTURY GROUP INC.	116
ACTAVIS, INC.	116
ALKALON A/S	117
BIOTA PHARMACEUTICALS, INC.	117
BIOTIE THERAPIES CORP.	117
BOEHRINGER INGELHEIM GMBH	118
CELTIC PHARMA MANAGEMENT L.P.	118
CIPLA LTD.	118
CYTOS BIOTECHNOLOGY AG	119
EVOTEC AG	119
FERTIN PHARMA A/S	119
GENTECH HEALTHCARE	120
GLAXOSMITHKLINE PLC	120
JOHNSON & JOHNSON	121
MCNEIL CONSUMER HEALTHCARE	121
NICONOVUM AB	121
NOVARTIS INTERNATIONAL AG	122
PERRIGO CO.	122
PFIZER INC.	122
PIERRE FABRE PHARMACEUTICALS INC.	123
LABORATOIRES PIERRE FABRE	123
PSYCOREMEDIES	123
REVOLYMER (U.K.) LTD.	124
SANOFI	124
SOMAXON PHARMACEUTICALS INC.	124
SOPHARMA AD	125
SUN PHARMACEUTICAL INDUSTRIES LTD.	125
TAISHO PHARMACEUTICAL HOLDINGS	125
TAKEDA PHARMACEUTICALS LTD.	126
TARGACEPT, INC.	126
WALGREENS	126
ZENARA PHARMACEUTICALS	127

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE SIZE OF GLOBAL SMOKING CESSATION MEDICINE MARKET BY REGION, THROUGH 2018 (\$ MILLIONS)	8
TABLE 1 BENEFITS OF SMOKING CESSATION	19
TABLE 2 GENERAL CRITERIA FOR DRUG DEPENDENCE	23
TABLE 3 CLASSIFICATION OF SMOKING CESSATION MEDICINES BASED ON MODE OF ACTION	29
TABLE 4 CLASSIFICATION OF NICOTINE REPLACEMENT THERAPY BASED ON DRUG DELIVERY SYSTEM	29
TABLE 5 NICOTINE GUM DOSAGES AND SCHEDULES	30
TABLE 6 KEY BRANDS AND MARKETERS OF NICOTINE GUMS	32
TABLE 7 NICOTINE LOZENGE DOSAGE AND SCHEDULE	32
TABLE 8 KEY BRANDS AND MARKETERS OF NICOTINE LOZENGES	33
TABLE 9 KEY BRANDS AND MARKETERS OF NICOTINE TABLETS	34
TABLE 10 KEY BRANDS AND MARKETERS OF NICOTINE INHALERS	34
TABLE 11 KEY BRANDS AND MARKETERS OF NICOTINE MOUTH SPRAYS	35
TABLE 12 NICOTINE PATCH DOSAGE AND SCHEDULE	36
TABLE 13 KEY BRANDS AND MARKETERS OF NICOTINE PATCHES	37
TABLE 14 KEY BRANDS AND MARKETERS OF NICOTINE NASAL SPRAYS	37
TABLE 15 CHANTIX/CHAMPIX SALES REVENUE, 2007-2012 (\$ MILLIONS)	39
TABLE 16 NICOTINE VACCINES IN DEVELOPMENT PHASE AS OF JANUARY 2013	41
TABLE 17 DEVELOPMENTS IN THE PIPELINE (NON-NICOTINE)	43
TABLE 18 CLINICAL TRIALS OF D-CYCLOSERINE	44
TABLE 19 SMOKING CESSATION MEDICINE GLOBAL MARKET FORECAST, THROUGH 2018 (\$ MILLIONS)	48
TABLE 20 SMOKING CESSATION MEDICINE GLOBAL MARKET FORECAST BY CLASSIFICATION, THROUGH 2018 (\$ MILLIONS)	49
TABLE 21 GLOBAL SMOKING CESSATION MEDICINES BY TYPE OF SALES	50
TABLE 22 SMOKING CESSATION MEDICINES FORECAST BY TYPE OF SALES, THROUGH 2018 (\$ MILLIONS)	51
TABLE 23 SIZE OF GLOBAL SMOKING CESSATION MEDICINE MARKET BY CATEGORY, THROUGH 2018 (\$ MILLIONS)	53
TABLE 24 GLOBAL NICOTINE REPLACEMENT THERAPY MARKET FORECAST BY CATEGORY, THROUGH 2018 (\$ MILLIONS)	56
TABLE 25 ARTICLES REPORTING HIGHEST IMPLEMENTATION RATES: 2012 WHO FCTC PROGRESS REPORT (%)	62
TABLE 26 ARTICLES REPORTING MODERATE IMPLEMENTATION RATES: 2012 WHO FCTC PROGRESS REPORT (%)	62
TABLE 27 ARTICLES REPORTING LOWEST IMPLEMENTATION RATES: 2012 WHO FCTC PROGRESS REPORT (%)	63
TABLE 28 GLOBAL IMPLEMENTATION OF FCTC ARTICLES: 2012 REPORT	64
TABLE 29 GLOBAL IMPLEMENTATION OF ARTICLE 14 OF FCTC, 2012	67
TABLE 30 SIZE OF GLOBAL SMOKING CESSATION MEDICINE MARKET BY REGION, THROUGH 2018 (\$ MILLIONS)	69
TABLE 31 SMOKING CESSATION BRANDS IN THE U.S. MARKET, 2012	72
TABLE 32 SMOKING CESSATION MEDICINE MARKET IN THE U.S., THROUGH 2018 (\$ MILLIONS)	73
TABLE 33 SMOKING CESSATION BRANDS IN CANADA MARKET: 2012	76
TABLE 34 SMOKING CESSATION MEDICINE MARKET IN CANADA, THROUGH 2018 (\$ MILLIONS)	77

TABLE HEADING	PAGE NO.
TABLE 35 SMOKING CESSATION BRANDS IN EUROPEAN MARKET: 2012	78
TABLE 36 SMOKING CESSATION MEDICINE MARKET IN EUROPE, THROUGH 2018 (\$ MILLIONS)	79
TABLE 37 SMOKING CESSATION BRANDS IN THE U.K. MARKET: 2012	81
TABLE 38 SMOKING CESSATION MEDICINE MARKET IN THE U.K., THROUGH 2018 (\$ MILLIONS)	82
TABLE 39 SMOKING CESSATION MEDICINE MARKET IN FRANCE, THROUGH 2018 (\$ MILLIONS)	84
TABLE 40 SMOKING CESSATION MEDICINE MARKET IN ASIA PACIFIC, THROUGH 2018 (\$ MILLIONS)	86
TABLE 41 SMOKING CESSATION BRANDS IN AUSTRALIA MARKET: 2012	88
TABLE 42 SMOKING CESSATION MEDICINE MARKET IN AUSTRALIA, THROUGH 2018 (\$ MILLIONS)	88
TABLE 43 SMOKING CESSATION BRANDS IN NEW ZEALAND MARKET: 2012	90
TABLE 44 SMOKING CESSATION MEDICINE MARKET IN EMERGING MARKETS, THROUGH 2018 (\$ MILLIONS)	93
TABLE 45 SMOKING CESSATION BRANDS IN INDIAN MARKET: 2012	98
TABLE 46 SMOKING CESSATION MEDICINE MARKET IN INDIA, THROUGH 2018 (\$ MILLIONS)	99
TABLE 47 SMOKING CESSATION BRANDS IN BRAZILIAN MARKET, 2012	100
TABLE 48 SMOKING CESSATION MEDICINE MARKET IN BRAZIL, THROUGH 2018 (\$ MILLIONS)	101
TABLE 49 INITIATIVES IMPLEMENTED BY PARTIES TO FCTC TREATY (%)	106
TABLE 50 PROJECTED GLOBAL CAUSE OF DEATH (%)	108
TABLE 51 PUBLIC HEALTH BURDEN DUE TO SMOKING-RELATED DISEASES (\$ BILLIONS)	108
TABLE 52 SWOT ANALYSIS OF SMOKING CESSATION MEDICINES	110
TABLE 53 COMPARING SMOKING CESSATION MEDICINES AND OTHER NICOTINE DELIVERY SYSTEMS	112

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE SIZE OF GLOBAL SMOKING CESSATION MEDICINE MARKET BY REGION, 2011-2018 (\$ MILLIONS)	8
FIGURE 1 NICOTINE MOLECULE: 3-[(2S)-1-METHYLPYRROLIDINE-2-YL]PYRIDINE	21
FIGURE 2 SMOKING CESSATION MEDICINE GLOBAL MARKET FORECAST, 2011-2018 (\$ MILLIONS)	48
FIGURE 3 SMOKING CESSATION MEDICINE GLOBAL MARKET FORECAST BY CLASSIFICATION, 2011-2018 (\$ MILLIONS)	50
FIGURE 4 SMOKING CESSATION MEDICINE GLOBAL MARKET FORECAST BY TYPE OF SALES, 2011-2018 (\$ MILLIONS)	51
FIGURE 5 SIZE OF GLOBAL SMOKING CESSATION MEDICINE MARKET BY CATEGORY, 2011-2018 (\$ MILLIONS)	53
FIGURE 6 GLOBAL NICOTINE REPLACEMENT THERAPY MARKET FORECAST BY CATEGORY, 2011-2018 (\$ MILLIONS)	56
FIGURE 7 GLOBAL IMPLEMENTATION OF ARTICLES: 2012 FTC REPORT (%)	63
FIGURE 8 SIZE OF GLOBAL SMOKING CESSATION MEDICINE MARKET BY REGION, 2011-2018 (\$ MILLIONS)	69
FIGURE 9 SMOKING CESSATION MEDICINE MARKET IN THE U.S., 2011-2018 (\$ MILLIONS)	73
FIGURE 10 SMOKING CESSATION MEDICINE MARKET IN EUROPE, 2011-2018 (\$ MILLIONS)	79
FIGURE 11 SMOKING CESSATION MEDICINE MARKET IN THE U.K., 2011-2018 (\$ MILLIONS)	82
FIGURE 12 SMOKING CESSATION MEDICINE MARKET IN FRANCE, 2011-2018 (\$ MILLIONS)	84
FIGURE 13 GLOBAL STUDIES ON TOBACCO DEPENDENCE AND SMOKING CESSATION, BY REGION (NO. OF ONGOING STUDIES)	109